US Patent 10308643 Heterocyclic compound
Patent 10308643 was granted and assigned to Takeda Pharmaceutical Company on June, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 9 Dec, 2023
Golden AI
Edits made to:
Article (+382 characters)
Article
Patent abstract
The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+7 properties)
Infobox
Patent Inventor Names
Akira Kaieda0
Hiroshi Nara0
Kousuke Hidaka0
Masaki Daini0
Masashi Toyofuku0
Masato Yoshikawa0
Naoki Ishii0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 3 Apr, 2023
Golden AI
Infobox
Patent Citations
Edits on 25 Sep, 2022
Golden AI
Infobox
Patent Citations
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 26 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10308643 Heterocyclic compound
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
10308643
Date of patent
June 4, 2019
Patent application number
15210965
Date Filed
July 15, 2016
Patent citations
Patent primary examiner
Find more entities like US Patent 10308643 Heterocyclic compound
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
